Stock listing
A3EGRS Stock Price, News, Filings & Events — Eupraxia Pharmaceuticals, Inc.
Selected listing: A3EGRS · LS · EUR · DE
This page tracks Eupraxia Pharmaceuticals, Inc.'s A3EGRS:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3EGRS:LS. A3EGRS:LS is the stock-level entry point for investors researching Eupraxia Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A3EGRS:LS
- Asset type
- Stock
- Market cap
- $483.5M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Eupraxia Pharmaceuticals, Inc. A3EGRS:LS stock context
This page tracks Eupraxia Pharmaceuticals, Inc.'s A3EGRS:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3EGRS:LS. A3EGRS:LS is the stock-level entry point for investors researching Eupraxia Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Eupraxia Pharmaceuticals, Inc.
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Pai...
August 13, 2026
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results 
August 11, 2026
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
July 13, 2026
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
July 7, 2026
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
June 19, 2026
Research Eupraxia Pharmaceuticals, Inc.
Eupraxia Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for A3EGRS:LS.
Eupraxia Pharmaceuticals, Inc. company profile
View the public company page for Eupraxia Pharmaceuticals, Inc. on 6ix.
Eupraxia Pharmaceuticals, Inc. news
Read company news and market updates connected to Eupraxia Pharmaceuticals, Inc..
Eupraxia Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Eupraxia Pharmaceuticals, Inc..
Alternate listings
EPRX:TSX
CA · CAD
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.
EPRX:NASDAQ
US · USD
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.
EPRX:NEO
CA · CAD
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.
A3EGRS:LSX
DE · EUR
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.
EPRX:BOATS
US · USD
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.
X43:FWB
DE · EUR
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.
X43:SWB
DE · EUR
Alternate listing for Eupraxia Pharmaceuticals, Inc.; the primary context on this page is A3EGRS:LS.